Trial Profile
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs ARRY 403 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Array BioPharma
- 11 Aug 2009 Results will be presented at a scientific meeting during the first half of 2010, according to an Array Biopharma media release.
- 11 Aug 2009 New trial record